Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A myelodysplastic/myeloproliferative neoplasm characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene. (WHO, 2001)
Biomarker and diagnostic research for atypical chronic myeloid leukemia, BCR-ABL1 negative has been reported in the published literature.
13 clinical trials registered, 5 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 5 PHASE2, 3 PHASE1, 1 EARLY_PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07238712](https://clinicaltrials.gov/study/NCT07238712) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 3:37 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
European rare disease database
Genetic and Rare Diseases Info Center
Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor |
PHASE2 |
St. Petersburg State Pavlov Medical University |
RECRUITING |
[NCT01137825](https://clinicaltrials.gov/study/NCT01137825) | Registry of Older Patients With Cancer | — | UNC Lineberger Comprehensive Cancer Center | RECRUITING |
[NCT05549661](https://clinicaltrials.gov/study/NCT05549661) | Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms | PHASE1 | Mayo Clinic | RECRUITING |
[NCT01137643](https://clinicaltrials.gov/study/NCT01137643) | Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer | — | UNC Lineberger Comprehensive Cancer Center | RECRUITING |
[NCT03964506](https://clinicaltrials.gov/study/NCT03964506) | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant | EARLY_PHASE1 | Omar Aljitawi | RECRUITING |
6 publications have been identified in PubMed for atypical chronic myeloid leukemia, BCR-ABL1 negative. Research spans Case Report / Case Series (33%), Epidemiology / Natural History (33%), and Diagnostic / Biomarker (17%).
Itonaga H (2026). [PMID: 41937388](https://pubmed.ncbi.nlm.nih.gov/41937388/). *Br J Haematol*. [Epidemiology / Natural History]
Zhou X (2025). [PMID: 40337600](https://pubmed.ncbi.nlm.nih.gov/40337600/). *Oncology letters*. [Case Report / Case Series]
Itonaga H (2025). [PMID: 39932123](https://pubmed.ncbi.nlm.nih.gov/39932123/). *American journal of hematology*. [Epidemiology / Natural History]
Badyal H (2025). [PMID: 40734882](https://pubmed.ncbi.nlm.nih.gov/40734882/). *Cureus*. [Case Report / Case Series]
Yan Z (2024). [PMID: 39225048](https://pubmed.ncbi.nlm.nih.gov/39225048/). *The journal of applied laboratory medicine*. [Diagnostic / Biomarker]
Szuber N (2024). [PMID: 38644693](https://pubmed.ncbi.nlm.nih.gov/38644693/). *American journal of hematology*. [Review / Meta-Analysis]